Literature DB >> 10676660

Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias.

A Bonati1, C Carlo-Stella, P Lunghi, R Albertini, S Pinelli, E Migliaccio, G Sammarelli, B Savoldo, A Tabilio, P P Dall'Aglio, P G Pelicci.   

Abstract

The BCR/ABL fusion protein is a constitutively active tyrosine kinase that is responsible for the pathogenesis of chronic myelogenous leukemia (CML). Clinically, CML is characterized by a chronic phase (CP) that eventually terminates into a blast crisis (BC). BC transformation is associated with accumulation of CD34+ blasts. We investigated the expression and phosphorylation of Src-homology-2 and collagen-homology domains (SHC) [corrected] proteins in subpopulations of CML primary cells. Shc polypeptides are tyrosine kinase substrates that are constitutively tyrosine-phosphorylated in continuous cell lines of CML origin. High levels of Shc expression were found in the CD34+ cells from CML-BC, CML-CP and normal bone marrow. In contrast, CD34- fractions from CML-CP and normal bone marrow expressed low levels of p46Shc. Shc proteins were constitutively phosphorylated in the CD34+ fractions from CML cells (both CP and BC), but not in normal CD34+ cells. These data bear implications for the role of Shc in normal hemopoiesis and CML leukemogenesis: (a) dramatic changes of Shc expression during terminal differentiation of hemopoietic cells adds a further level of regulation to the signal transduction function of Shc; and (b) constitutive Shc tyrosine-phosphorylation in the rare CD34+ cells of CML-CP might contribute to the selection of this subpopulation during the blast crisis transformation of CMLs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676660

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Propofol protects against angiotensin II-induced mouse hippocampal HT22 cells apoptosis via inhibition of p66Shc mitochondrial translocation.

Authors:  Minmin Zhu; Jiawei Chen; Meilin Wen; Zhirong Sun; Xia Sun; Jing Wang; Changhong Miao
Journal:  Neuromolecular Med       Date:  2014-08-24       Impact factor: 3.843

2.  Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.

Authors:  Theresa Klümper; Henrike Bruckmueller; Tobias Diewock; Meike Kaehler; Sierk Haenisch; Christiane Pott; Oliver Bruhn; Ingolf Cascorbi
Journal:  Exp Hematol Oncol       Date:  2020-09-26

3.  The G protein-coupled estrogen receptor-1, GPER-1, promotes fibrillogenesis via a Shc-dependent pathway resulting in anchorage-independent growth.

Authors:  Hilary T Magruder; Jeffrey A Quinn; Jean E Schwartzbauer; Jonathan Reichner; Allan Huang; Edward J Filardo
Journal:  Horm Cancer       Date:  2014-08-06       Impact factor: 3.869

Review 4.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

5.  Genetic screen for regulators of lymph gland homeostasis and hemocyte maturation in Drosophila.

Authors:  Kai Li Tan; Siow Chong Goh; Svetlana Minakhina
Journal:  G3 (Bethesda)       Date:  2012-03-01       Impact factor: 3.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.